We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Deletion of the FOXO1 Gene Transforms Intestinal Cells into Insulin Producers

By LabMedica International staff writers
Posted on 13 Jul 2014
After having demonstrated that gut endocrine progenitor cells of mice could be differentiated into glucose-responsive, insulin-producing cells by elimination of the transcription factor FOXO1 (forkhead box O1), diabetes researchers have extended these findings by obtaining similar results with human gut endocrine progenitor and serotonin-producing cells.

Generation of alternative sources of insulin-producing beta-cells has been a goal of researchers in the field of diabetes therapy. More...
While most efforts have been directed at differentiating embryonic or induced pluripotent stem (iPS) cells into beta-like-cells, investigators at Columbia University (New York, NY, USA) have shown that shown that mouse intestinal cells could be transformed into insulin-producing cells by deactivating the cells’ FOXO1 gene.

In a paper published in the June 30, 2014, online edition of the journal Nature Communications, the investigators revealed that FOXO1 was present in human gut endocrine progenitor and serotonin-producing cells. Using gut organoids derived from human iPS cells, they demonstrated that inhibition of FOXO1 using a dominant-negative mutant or Lentivirus-encoded small hairpin RNA promoted generation of insulin-positive cells that expressed all markers of mature pancreatic beta-cells and survived in vivo following transplantation into mice.

“People have been talking about turning one cell into another for a long time, but until now we had not gotten to the point of creating a fully functional insulin-producing cell by the manipulation of a single target,” said senior author Dr. Domenico Accili, professor of diabetes at Columbia University. “By showing that human cells can respond in the same way as mouse cells, we have cleared a main hurdle and can now move forward to try to make this treatment a reality.”

Related Links:

Columbia University



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.